✨ Free AI Report
Adagene Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Adagene Inc.
Company Research

Adagene Inc.: Business Overview, Financials & Competitive Analysis

Adagene Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage biotech with differentiated AI-driven antibody platform; success depends on Phase 2 trial outcomes and partnership value realization in oncology immunotherapy space. Adagene demonstrates strong scientific positioning with differentiated antibody platforms and multiple pharma partnerships (Sanofi, Merck, Exelixis). However, as a clinical-stage biotech with limited commercial revenue, regulatory and clinical.

What is Adagene Inc.'s industry? Adagene Inc. (adagene.com) operates in Biopharmaceutical - Oncology Immunotherapy. AskCyborg classifies Adagene Inc. under Biopharmaceutical - Oncology Immunotherapy in its company registry.

Adagene is a biotechnology company developing novel antibody-based cancer immunotherapies, combining computational biology and artificial intelligence to design antibodies addressing unmet patient needs. The company l...

6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with differentiated AI-driven antibody platform; success depends on Phase 2 trial outcomes and partnership...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology Immunotherapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Adagene Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Adagene Inc.

AskCyborg analysts argue the bull and bear cases for Adagene Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Adagene Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Adagene Inc. Overview

Pro stress-test →

Adagene is a biotechnology company developing novel antibody-based cancer immunotherapies, combining computational biology and artificial intelligence to design antibodies addressing unmet patient needs. The company leverages a proprietary AI-powered DPL (Dynamic Precision Library) platform that explores dynamic conformational diversity of protein sequences as a new paradigm for antibody drug discovery.

Strategic Profile

Pro stress-test →

Adagene's highly differentiated pipeline features novel immunotherapy programs powered by its DPL platform, composed of NEObody, SAFEbody™, and POWERbody™ technologies. The company recently expanded its partnership with Sanofi with a strategic investment of up to $25 million to fund development of ADG126, its masked anti-CTLA-4 program, through a randomized Phase 2 trial in microsatellite stable colorectal cancer.

Competitive Landscape

Pro stress-test →

Adagene competes in the antibody immunotherapy space against companies developing novel cancer treatments. The company differentiates through its AI-powered DPL platform and multi-technology approach (NEObody, SAFEbody, POWERbody). Strategic partnerships with major pharma (Sanofi, Merck, Exelixis, ADC Therapeutics) indicate competitive strength, though development programs remain largely in clinical stages.

Industry Context

Adagene Inc. operates in Biopharmaceutical - Oncology Immunotherapy.

Key facts

Founded: 2011 · Headquarters: Suzhou, China · Revenue: $50M-$100M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Adagene Inc..

  • ADG126 advanced into Phase 2 following FDA endorsement, with the company moving toward patient enrollment to define optimal dose for Phase 3
  • Partnership expansion with Sanofi demonstrates validation of SAFEbody platform for masked antibody therapies in colorectal cancer
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Partnership with Third HealthCare for antibody development
  • September 2025Amendment to Exelixis collaboration expanding SAFEbody platform usage for ADC development
  • +2 moreTrack every material event for Adagene Inc. as it happens. Explore monitoring →
Get alerted when Adagene Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Anti-CD137 mAbsCompeting agonistic antibody approaches in immuno-oncology→Masked CTLA-4 inhibitorsAlternative approaches to ADG126 in colorectal cancer→Antibody-Drug ConjugatesCompetitive platforms for precision oncology→

Compare Adagene Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Adagene Inc. operates in Biopharmaceutical - Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Adagene Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Adagene Inc. and its top competitor on Cyborg Score”
“What did Adagene Inc. do this quarter?”
“Is Adagene Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Adagene Inc. do?+
Adagene is a biotechnology company developing novel antibody-based cancer immunotherapies, combining computational biology and artificial intelligence to design antibodies addressing unmet patient needs. The company l...
What is Adagene Inc.'s Cyborg Score?+
Adagene Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Adagene Inc.'s main competitors?+
Named competitors include Anti-CD137 mAbs, Masked CTLA-4 inhibitors, Antibody-Drug Conjugates. The full competitive landscape is in the AskCyborg report.
How can I get the full Adagene Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Adagene Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Adagene Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.